Display options
Cite
Bröckelmann PJ, Müller H, Gillessen S, et al. Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis. Leukemia. 2021;doi: 10.1038/s41375-021-01442-8.
Bröckelmann, P. J., Müller, H., Gillessen, S., Yang, X., Koeppel, L., Pilz, V., Marinello, P., Kaskel, P., Raut, M., Fuchs, M., Borchmann, P., Engert, A., & von Tresckow, B. (2021). Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis. Leukemia, . https://doi.org/10.1038/s41375-021-01442-8
Bröckelmann, Paul J, et al. "Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis." Leukemia vol. (2021). doi: https://doi.org/10.1038/s41375-021-01442-8
Bröckelmann PJ, Müller H, Gillessen S, Yang X, Koeppel L, Pilz V, Marinello P, Kaskel P, Raut M, Fuchs M, Borchmann P, Engert A, von Tresckow B. Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis. Leukemia. 2021 Oct 09; doi: 10.1038/s41375-021-01442-8. Epub 2021 Oct 09. PMID: 34628472.
Copy Download .nbib Format: NLM
Share it on

Leukemia. 2021 Oct 09; doi: 10.1038/s41375-021-01442-8. Epub 2021 Oct 09.

Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis.

Leukemia

Paul J Bröckelmann, Horst Müller, Sarah Gillessen, Xiaoqin Yang, Larissa Koeppel, Veronika Pilz, Patricia Marinello, Peter Kaskel, Monika Raut, Michael Fuchs, Peter Borchmann, Andreas Engert, Bastian von Tresckow

Affiliations

  1. Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Cologne, Germany.
  2. German Hodgkin Study Group (GHSG), University of Cologne, Cologne, Germany.
  3. Cancer Center Cologne Essen (CCCE), Cologne/Essen, Germany.
  4. Merck & Co., Inc, Kenilworth, NJ, USA.
  5. MSD Sharp & Dohme GmbH, Haar, Germany.
  6. German Hodgkin Study Group (GHSG), University of Cologne, Cologne, Germany. [email protected].
  7. Cancer Center Cologne Essen (CCCE), Cologne/Essen, Germany. [email protected].
  8. Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. [email protected].

PMID: 34628472 DOI: 10.1038/s41375-021-01442-8

Abstract

To evaluate patterns of rrHL after contemporary first-line treatment we studied 409 patients with first rrHL (HD13: n = 87, HD14: n = 118, HD15: n = 188, HDR3i: n = 51) at a median age of 37.4 years (18.4-76.8) from the GHSG database. Time to first relapse was ≤12 months in 49% and stage III/IV rrHL present in 52% of patients. In total, 291 patients received high-dose chemotherapy and autologous stem-cell transplantation (ASCT) and intended ASCT failed in 38 patients. ASCT was primarily not intended in 80 patients largely due to low risk disease or age/comorbidities. Overall, 10-year progression-free (PFS) and overall survival (OS) rates after first relapse were 48.2% (95% CI 41.9-54.2%) and 59.4% (95% CI 53.0-65.2%), respectively, with significant differences between subgroups. Inferior survival was observed with no ASCT due to advanced age/comorbidities (five-year PFS 36.2%, 95% CI 17.7-55.0%) or failure of salvage therapy (five-year PFS 36.3%, 95% CI 19.7-53.2%). Similarly, presence of primary refractory disease or stage IV at rrHL conferred inferior survival. In patients with low-risk disease, however, survival appeared favorable even without ASCT (10 y PFS 72.6%, 95% CI 53.7-84.8%). We herein confirm the curative potential of current rrHL treatments providing a robust benchmark to evaluate novel therapeutic strategies in rrHL. Approximately 50% of rrHL patients experienced a consecutive relapse.

© 2021. The Author(s).

References

  1. Bröckelmann PJ, Eichenauer DA, Jakob T, Follmann M, Engert A, Skoetz N. Clinical practice guideline: Hodgkin lymphoma in adults—diagnosis, treatment, and follow-up. Deutsches Arzteblatt International. 2018. https://doi.org/10.3238/arztebl.2018.0535 . - PubMed
  2. Sasse S, Bröckelmann PJ, Goergen H, Plütschow A, Müller H, Kreissl S et al. Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: Updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 trials. J of Clin Oncol. 2017; 35. https://doi.org/10.1200/JCO.2016.70.9410 . - PubMed
  3. Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, et al. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2017;390:2790–2802. - PubMed
  4. von Tresckow B, Kreissl S, Goergen H, Bröckelmann PJ, Pabst T, Fridrik M, et al. Intensive treatment strategies in advanced-stage Hodgkin’s lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. Lancet Haematol. 2018;5:e462–e473. - PubMed
  5. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359:2065–2071. - PubMed
  6. Rancea M, Monsef I, von Tresckow B, Engert A, Skoetz N. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. Cochrane Database of Syst Rev. 2013; 2013. https://doi.org/10.1002/14651858.CD009411.pub2 . - PubMed
  7. Josting A, Müller H, Borchmann P, Baars JW, Metzner B, Döhner H, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin’s lymphoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2010;28:5074–80. - PubMed
  8. Bröckelmann PJ, Müller H, Guhl T, Behringer K, Fuchs M, Moccia AA et al. Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy. J Clin Oncol. 2021;39:107–115. - PubMed
  9. Moskowitz AJ, Hamlin PA, Perales MA, Gerecitano J, Horwitz SM, Matasar MJ, et al. Phase ii study of bendamustine in relapsed and refractory hodgkin lymphoma. J Clin Oncol. 2013;31:456–460. - PubMed
  10. Santoro A, Bredenfeld H, Devizzi L, Tesch H, Bonfante V, Viviani S, et al. Gemcitabine in the treatment of refractory Hodgkin’s disease: results of a multicenter phase II study. J Clin Oncol. 2000;18:2615–2619. - PubMed
  11. Bröckelmann PJ, Müller H, Kücüksarioglan E, Kaskel P, Metterlein V, Giezek H, et al. Outcomes of patients with the third or higher relapsed classical Hodgkin lymphoma: Results from the German Hodgkin Study Group. Ann Oncol. 2019;30:490–491. - PubMed
  12. Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2012;97:310–317. - PubMed
  13. Josting A, Nogová L, Franklin J, Glossmann J-P, Eich HT, Sieber M, et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol: Off J Am Soc Clin Oncol. 2005;23:1522–9. - PubMed
  14. Bröckelmann PJ, Angelopoulou MK, Vassilakopoulos TP. Prognostic factors in Hodgkin lymphoma. Semin Hematol. 2016;53:155–164. - PubMed
  15. Bröckelmann PJ, Müller H, Casasnovas O, Hutchings M, von Tresckow B, Jürgens M et al. Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma. Annals of Oncology. 2017; 28. https://doi.org/10.1093/annonc/mdx072 . - PubMed
  16. Arai S, Fanale M, Devos S, Engert A, Illidge T, Borchmann P, et al. Defining a hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma. 2013;54:2531–2533. - PubMed
  17. Böll B, Goergen H, Arndt N, Meissner J, Krause SW, Schnell R, et al. Relapsed Hodgkin lymphoma in older patients: a comprehensive analysis from the German Hodgkin study group. J Clin Oncol. 2013;31:4431–4437. - PubMed
  18. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30:2183–2189. - PubMed
  19. Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17:1283–1294. - PubMed
  20. Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin Lymphoma. J of Clin Oncol. 2017. https://doi.org/10.1200/JCO.2016.72.1316 . - PubMed
  21. Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385:1853–1862. - PubMed
  22. Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson N, et al. KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL). J Clin Oncol. 2020;38:8005–8005. - PubMed
  23. Viele K, Berry S, Neuenschwander B, Amzal B, Chen F, Enas N, et al. Use of historical control data for assessing treatment effects in clinical trials. Pharm Stat. 2014;13:41–54. - PubMed
  24. Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, et al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin’s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet. 2015;385:1418–27. - PubMed
  25. von Tresckow B, Plütschow A, Fuchs M, Klimm B, Markova J, Lohri A, et al. Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol: Off J Am Soc Clin Oncol. 2012;30:907–13. - PubMed
  26. Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379:1791–1799. - PubMed
  27. von Tresckow B, Hüttmann A, Vucinic V, Mueller H, Plütschow A, Viardot A, et al. Induction Therapy with Everolimus in Combination with DHAP (Dexamethasone, High-Dose AraC, Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: A Randomized, Placebo-Controlled Phase I/II Trial (HD-R3i). Blood. 2018;132:2912. - PubMed
  28. Moskowitz AJ, Schöder H, Yahalom J, McCall SJ, Fox SY, Gerecitano J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: A non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16:284–292. - PubMed
  29. Kersten MJ, Driessen J, Zijlstra JM, Plattel WJ, Morschhauser F, Lugtenburg PJ et al. Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study. Haematologica 2020;: haematol.2019.243238. - PubMed
  30. Moskowitz CH, Matasar MJ, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin P, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2012;119:1665–1670. - PubMed
  31. Kanate AS, Kumar A, Dreger P, Dreyling M, Le Gouill S, Corradini P, et al. Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas after Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT. JAMA Oncol. 2019;5:715–722. - PubMed
  32. Sibon D, Morschhauser F, Resche-Rigon M, Ghez D, Dupuis J, Marçais A, et al. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group. Haematologica. 2016;101:474–481. - PubMed
  33. Moskowitz CH, Yahalom J, Zelenetz AD, Zhang Z, Filippa D, Teruya-Feldstein J, et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging: Research paper. Br J Haematol. 2010;148:890–897. - PubMed
  34. Bröckelmann PJ, Goergen H, Kohnhorst C, von Tresckow B, Moccia A, Markova J et al. Late relapse of classical Hodgkin lymphoma: an analysis of the German Hodgkin Study Group HD7 to HD12 trials. J of Clin Oncol. 2017; 35. https://doi.org/10.1200/JCO.2016.71.3289 . - PubMed
  35. Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132:2639–2642. - PubMed
  36. Eichenauer DA, Plütschow A, Kreissl S, Sökler M, Hellmuth JC, Meissner J, et al. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin’s lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. Lancet Oncol. 2017;18:1680–1687. - PubMed
  37. Bröckelmann PJ, Goergen H, Keller U, Meissner J, Ordemann R, Halbsguth TV et al. Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma. JAMA Oncol. 2020. https://doi.org/10.1001/jamaoncol.2020.0750 . - PubMed
  38. Allen PB, Savas H, Evens AM, Advani R, Palmer B, Pro B et al. Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma. Blood 2020. https://doi.org/10.1182/blood.2020007400 . - PubMed
  39. Crump M. Time to change direction in the treatment of relapsed Hodgkin lymphoma? J Clin Oncol. 2021;39:97–99. - PubMed

Publication Types